|Mr. John A. Kollins||Pres, CEO & Director||585.79k||N/A||1963|
|Mr. Thomas P. O'Neil||Chief Financial Officer||436.96k||N/A||1965|
|Dr. Detlef F. Albrecht||Chief Medical Officer||501.15k||N/A||1961|
|Mr. Mic Iwashima||VP & Head of Operations||N/A||N/A||1978|
|Mr. Robert Schultz||VP & Head of CMC||N/A||N/A||1964|
|Dr. Shannon Strom Ph.D.||VP & Head of Regulatory Affairs||N/A||N/A||1976|
|Mr. Robert M. Janosky||Chief Commercial Officer||N/A||N/A||N/A|
|Mr. Alan C. Mendelson J.D.||Sec.||N/A||N/A||1950|
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.